logo
#

Latest news with #MedicalMarijuana

Medical marijuana business owner reacts to software glitch
Medical marijuana business owner reacts to software glitch

Yahoo

time15-05-2025

  • Business
  • Yahoo

Medical marijuana business owner reacts to software glitch

OKLAHOMA CITY (KFOR) — Thousands of medical marijuana business owners were likely in full-blown panic mode Wednesday morning after a glitch in a system that the Oklahoma Medical Marijuana Authority (OMMA) uses. Many woke up to find out their business licenses had been suddenly canceled. The state blames all of it on a software glitch, and this is not the first time the program has caused problems for state agencies. Software glitch cancels thousands of Medical Marijuana business licenses OMMA says In the few years that this company has been operating in Oklahoma, there have been multiple problems. The latest issue came on Wednesday morning, likely causing medical marijuana business owners' hearts to drop. 'They basically told us that our licenses were expired,' said Todd Curtis, Owner of Old McDoobie's Pharm Too. 'We couldn't operate anymore.' OMMA sent out a message after an apparent glitch suddenly canceled thousands of commercial Medical Marijuana licenses overnight. 'It's very nerve-racking,' Curtis said. 'I mean, you're sitting on a lot of product and a lot of money. The OMMA sends out a letter that says, 'We've basically wrecked your life and everybody else around you.'' OMMA said this was due to a glitch in the system they use for licensing. From what we understand so far, a glitch in the licensing system canceled thousands of commercial licenses overnight. We're actively working with the third-party vendor to figure out what led to this and the inconvenience it put on thousands of businesses. Businesses that received this cancelation notice can continue to operate and should report the issue via our contact form at Within the next fiscal year, we'll be launching a new licensing software platform. OMMA The third-party vendor is Thentia, which the OMMA proudly promotes on its website as 'a better way to license.' The licensing software platform arrived in Oklahoma just a few years ago, but there have been several problems with state agencies since then, including outages, trouble reading payments, and issues tracking certain education credits, according to a 2023 report by Oklahoma Watch. News 4 reached out to Thentia's Oklahoma City office, but have not heard back. In the meantime, OMMA says every business that received the cancellation notice should report it to them, adding they can continue to operate, but Curtis says he's still worried. 'I don't think we've even gotten anything back that says, you know, we're not expired,' Curtis said. 'So, it's still nerve-wracking.' OMMA says it will move away from Thentia as its licensing software within the next fiscal year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Cannabidiol Market to Hit $22.05 Billion by 2030 at CAGR 15.8% - Grand View Research, Inc.
Cannabidiol Market to Hit $22.05 Billion by 2030 at CAGR 15.8% - Grand View Research, Inc.

Yahoo

time13-05-2025

  • Business
  • Yahoo

Cannabidiol Market to Hit $22.05 Billion by 2030 at CAGR 15.8% - Grand View Research, Inc.

SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- The global cannabidiol market size is expected to reach USD 22.05 billion by 2030, according to a new study by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.8% from 2025 to 2030. Changing consumer attitudes towards CBD products, shifting public opinion, and growing recognition of the health benefits of cannabidiol are some of the main factors contributing to the market's growth. The cannabis Sativa plant contains more than 80 cannabinoids, but cannabidiol is the most widely used for medical purposes because of its lack of psychoactive effects. It is primarily obtained from hemp due to its high CBD content. There is a high demand for various CBD-infused products, such as beauty products, cannabis oil, beverages, gummies, capsules, etc. CBD can enter the human body through different means, including vaping, smoking, and through the skin. In the U.S., where cannabis is legal, CBD is utilized to produce personal care products and medical drugs. Legalizing cannabis-based products has opened up significant opportunities for various end-use industries to expand their product offerings. Request a free sample copy or view report summary: Cannabidiol Market Major players in the industry are focused on introducing CBD-infused products. Companies are exploring opportunities in international markets as the demand for CBD grows globally. Furthermore, they are investing in research and development to enhance the effectiveness and efficiency of their products, as well as to expand their offerings. The players are introducing new and innovative products, such as edibles, topicals, and beverages, to cater to the growing demand. For instance, in May 2022, Medical Marijuana, Inc. announced the launch of a pharma subsidiary in Brazil named "HM Pharma" to expand its access to CBD products in pharmacies. Cannabidiol Market Report Highlights: North America accounts for the largest with a market share of 86.7% in 2024 owing to the presence of major manufacturers, and approval of the U.S. Farm Bill are some of the major factors driving the growth of the region. Hemp-derived CBD dominated the market in 2024, with a market share owing to its higher purity and potential health benefits. B2B segment accounts for the largest market share in 2024 owing to increasing demand and a rising number of businesses using cannabidiol as raw materials. In 2023, the pharmaceuticals segment accounted for the largest market share in the end-use market owing to rising use of cannabis derivate for various medical conditions. Read full market research report on Cannabidiol Market with TOC - Cannabidiol Market Size, Share & Trends Analysis Report By Source Type (Hemp, Marijuana), By Sales Type (B2B, B2C), By End-use (Medical, Personal Use), By Region, And Segment Forecasts, 2025 - 2030 Cannabidiol Market Segmentation Grand View Research has segmented the global cannabidiol market based on source type, sales type, end-use, and region: Cannabidiol (CBD) Market - Source Type Outlook (Revenue, USD Million, 2018 - 2030) Hemp Marijuana Cannabidiol (CBD) Market - Sales Type Outlook (Revenue, USD Million, 2018 - 2030) B2B By End-use Pharmaceuticals Wellness Food & Beverages Personal Care & Cosmetics Nutraceuticals Others B2C By Sales Channel Hospital Pharmacies Online Retail Stores By End-use Medical Chronic Pain Mental Disorders Cancer Others Personal Use Cannabidiol (CBD) Market - End-use Outlook (Revenue, USD Million, 2018 - 2030) Medical Personal Use Pharmaceuticals Wellness Cannabidiol (CBD) Market - Regional Outlook (Revenue, USD Million, 2018 - 2030) North America Europe Asia Pacific Latin America Middle East & Africa (MEA) List of Key Players in the Cannabidiol Market ENDOCA Cannoid, LLC Medical Marijuana, Inc. Folium Europe B.V. Canopy Growth Corporation Elixinol NuLeaf Naturals, LLC Isodiol International, Inc. PharmaHemp The Cronos Group Check out more related studies published by Grand View Research: U.S. Cannabinoids Market - The U.S. cannabinoids market size is expected to reach USD 60.36 billion by 2030, registering a CAGR of 15.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing number of consumers opting for isolated cannabinoid products aided by growing clinical studies to understand and expand applications associated with cannabinoids is driving the growth of the overall market in the U.S. Latin America And Caribbean Hemp-Derived Cannabidiol Market - The Latin America and Caribbean hemp-derived cannabidiol market size is estimated to reach USD 524.39 million by 2030, expanding at a CAGR of 18.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The LATAM and Caribbean regions have a huge potential to become the leader in hemp and cannabidiol space owing to the vast agriculture industry, low labor, and construction costs. North America Hemp-derived Cannabidiol Market - The North America hemp-derived cannabidiol market size is expected to reach USD 3.1 billion by 2030. It is expected to expand at a compound annual growth rate (CAGR) of 13.5% over the forecast period, according to a new report by Grand View Research, Inc. Growing awareness and adoption of cannabidiol (CBD) for various health conditions are the key factors driving the growth of this market. Mexico Hemp CBD Market - The Mexico hemp CBD market size is projected to reach USD 74.3 million by 2030, expanding at a revenue-based CAGR of 26.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The recent approval by the Mexico government for the usage of medical cannabis and cannabidiol-derived products containing less than 1% Tetrahydrocannabinol (THC) is driving the market. Browse Horizon Databook on Cannabidiol Market – Global Cannabidiol Market Size & Outlook About Grand View Research Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead. Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research. Gain insights from 30K+ Global & Regional Reports, 120K+ Country Reports, 1.2M+ Market Statistics, 200K+ Company Profiles, and 5 business solutions encompassing ESG and Sustainability Consulting, Procurement Intelligence, Pricing Index and Analysis, and Consumer Analytics. Contact: Sherry JamesCorporate Sales Specialist, USAGrand View Research, 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@ Us: LinkedIn | TwitterBlog - Logo: View original content: SOURCE Grand View Research, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Supreme Court allows truck driver's lawsuit against CBD maker
Supreme Court allows truck driver's lawsuit against CBD maker

Washington Post

time02-04-2025

  • Washington Post

Supreme Court allows truck driver's lawsuit against CBD maker

The Supreme Court cleared the way Wednesday for a truck driver to sue the company that sold him a cannabidiol, or CBD, product that he says led to him getting fired after testing positive for THC. In a 5-4 ruling, the justices upheld an appeals court decision that allowed Douglas Horn to take legal action against Medical Marijuana, Inc., under a landmark federal law that is better known as a tool used by prosecutors to target organized crime.

Supreme Court sides with truck driver who said CBD got him fired
Supreme Court sides with truck driver who said CBD got him fired

USA Today

time02-04-2025

  • Business
  • USA Today

Supreme Court sides with truck driver who said CBD got him fired

Supreme Court sides with truck driver who said CBD got him fired Douglas Horn, the truck driver, had taken the supplement to help his chronic back and shoulder pain. The company promised the hemp-based product, Dixie X, did not contain THC. Show Caption Hide Caption What we know about key SCOTUS cases that could impact you The Supreme Court is beginning a new term and is set to hear a range of big cases. Here's what we know now. WASHINGTON – The Supreme Court on Wednesday sided with a truck driver who lost his job after taking a hemp-based supplement. In a 5-4 decision, the court said Douglas Horn can use an anti-racketeering law to sue the supplement manufacturer he said falsely advertised its 'new CBD-rich medicine' as not containing TCH, the active ingredient in marijuana. Horn said the supplement, Dixie X, caused him to fail a drug test and he should be able to use a federal law created to fight organized crime to recover lost wages. Under the Racketeer Influenced and Corrupt Organizations Act, Horn could get triple damages and attorney fees if he can prove his case. The manufacturer, Medical Marijuana Inc., argued that RICO can't be used to sue for personal injuries, only for harm to 'business or property.' Horn contended that the harm was to his ability to earn a living, which meets the plain definition of 'business.' Writing for the majority, Justice Amy Coney Barrett said Medical Marijuana "tried valiantly to engineer a rule that yields its preferred outcomes." "When all is said and done, Medical Marijuana is left fighting the most natural interpretation of the text − that 'injured' means 'harmed' − with no plausible alternative in hand," she wrote. "That is a battle it cannot win." Justices Clarence Thomas, Brett Kavanaugh, Samuel Alito and Chief Justice John Roberts dissented. During the October oral arguments, some conservative justices expressed concern that allowing that interpretation would open the floodgates to the types of lawsuits the law wasn't intended to cover. That was also a point raised in a legal filing by the U.S. Chamber of Commerce, which urged the court to rule against Horn. Otherwise, the group said, there will be 'devastating consequences' from increasing businesses' exposure to lawsuits. The truck driver's lawyers argued there are still significant hurdles for using RICO. Anyone making a claim has to show a pattern of racketeering activity and that the illegal activities caused the injury, Easha Anand, an attorney for Horn, told the Supreme Court. Created primarily to fight organized crime, RICO was seldom used until a 1981 Supreme Court decision expanded its interpretation to apply to both legitimate and illegitimate enterprises, according to Jeffrey Grell, an expert on the law who previewed the case for the American Bar Association. But after the federal courts were deluged with RICO cases, the Supreme Court has tried to limit its application. The case is Medical Marijuana Inc. v. Horn.

Supreme Court sides with trucker fired after CBD product triggered failed drug test
Supreme Court sides with trucker fired after CBD product triggered failed drug test

Yahoo

time02-04-2025

  • Business
  • Yahoo

Supreme Court sides with trucker fired after CBD product triggered failed drug test

The Supreme Court sided with a former commercial truck driver Wednesday who was fired after failing a drug test he said was caused by a 'CBD-rich medicine' in a decision that could make it easier to sue companies under organized crime laws. Douglas Horn sued the manufacturers of a CBD product called 'Dixie X' that the companies proclaimed included no THC, the psychoactive ingredient in marijuana. Horn took the product to manage debilitating pain after a serious accident, but he later failed a drug test and was fired. The Supreme Court's decision will allow Horn's case to move forward in lower courts. Justice Amy Coney Barrett wrote the opinion for a 5-4 majority that included both liberal and conservative justices. 'When all is said and done, Medical Marijuana is left fighting the most natural interpretation of the text – that 'injured' means 'harmed' – with no plausible alternative in hand,' Barrett wrote. 'That is a battle it cannot win.' Horn sued under the Racketeer Influenced and Corrupt Organizations, or RICO, Act, a 1970 law targeted at organized crime that also authorizes civil lawsuits – and allows plaintiffs to collect triple damages – for harm to their business or property. The question for the Supreme Court was whether Horn's loss of employment qualified as a business harm. Medical Marijuana, Inc., and other companies involved in distributing Dixie X, argued that Horn's injury was a personal one – and therefore not a business or property harm as required in the law. Congress, the companies argued, didn't intend for Americans to be able to collect triple damages under the RICO law for run-of-the-mill injury claims. Horn sued in the Western District of New York in 2015, alleging in part that Medical Marijuana Inc. engaged in mail and wire fraud. The district court ruled against Horn, but the New York-based 2nd US Circuit Court of Appeals allowed his suit to move forward. The companies appealed to the Supreme Court. Allowing Horn to sue, the companies said, would vastly expand the number and type of 'civil RICO' lawsuits permeating through federal courts. Concern over a flood of new lawsuits appeared to resonate with several of the court's conservatives during the oral arguments in October. But other justices suggested during arguments that a loss of employment would fall under what most Americans view as an ordinary definition of 'business.' 'If you're harmed when you lose a job, then you've been injured in your business, haven't you?' Justice Elena Kagan, a member of the court's liberal wing, asked the lawyer for the companies. The law, Kagan said, 'just says if you've been injured by a RICO violation in your business, which includes your employment, then you're entitled to threefold damages.' President Richard Nixon signed the federal RICO Act in 1970 to give prosecutors more power to go after the heads of organized crime families. Several states have enacted their own versions of the law. In Georgia, prosecutors were attempting to use a state RICO law to prosecute Donald Trump for his efforts to overturn the 2020 election results there. This story has been updated with additional details.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store